Skip to main content
Erschienen in: Journal of Gastrointestinal Surgery 11/2007

01.11.2007

Clinicopathologic Features and Treatment Trends of Pancreatic Neuroendocrine Tumors: Analysis of 9,821 Patients

verfasst von: Karl Y. Bilimoria, James S. Tomlinson, Ryan P. Merkow, Andrew K. Stewart, Clifford Y. Ko, Mark S. Talamonti, David J. Bentrem

Erschienen in: Journal of Gastrointestinal Surgery | Ausgabe 11/2007

Einloggen, um Zugang zu erhalten

Abstract

The natural history of pancreatic neuroendocrine tumors (PNET) remains poorly defined. Our objectives were to examine the clinicopathologic features of PNETs, to assess treatment trends over time, and to identify factors associated with undergoing resection. From the National Cancer Data Base (1985–2004), 9,821 patients were identified with PNETs. Clinicopathologic features and treatment trends were examined. Multivariable logistic regression was used to assess factors associated with undergoing resection. Of 9,821 patients with PNETs, 85% were nonfunctional, 7.1% were functional, and 7.9% were carcinoid tumors. Of the 3,851 (39.0%) patients who underwent pancreatectomy, 449 (11.7%) received adjuvant chemotherapy, and 254 (6.6%) received adjuvant radiation. From 1985 to 2004, utilization of pancreatectomy increased from 39.4 to 44.3% (P < 0.0001). Patients were less likely to undergo resection if they were >55 years old, had tumors in the head of the pancreas, tumors ≥4 cm, or had distant metastases (P < 0.0001). Patients treated at NCCN/NCI, academic, or high-volume hospitals were more likely to undergo resection. There are disparities in the utilization of pancreatectomy for PNETs. As PNETs have a better prognosis than adenocarcinoma, concerns regarding the morbidity and mortality of pancreatic surgery and neoplasms should not preclude resection.
Literatur
1.
Zurück zum Zitat Mullan MH, Gauger PG, Thompson NW. Endocrine tumours of the pancreas: review and recent advances. ANZ J Surg 2001;71(8):475–482.PubMedCrossRef Mullan MH, Gauger PG, Thompson NW. Endocrine tumours of the pancreas: review and recent advances. ANZ J Surg 2001;71(8):475–482.PubMedCrossRef
2.
Zurück zum Zitat Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005;14(7):1766–1773.PubMedCrossRef Fesinmeyer MD, Austin MA, Li CI, et al. Differences in survival by histologic type of pancreatic cancer. Cancer Epidemiol Biomarkers Prev 2005;14(7):1766–1773.PubMedCrossRef
3.
Zurück zum Zitat Fitzgerald T, Hickner Z, Schmitz M, et al. Increasing incidence of nonfunctional neuroendocrine tumors of the pancreas. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL., 2007. Fitzgerald T, Hickner Z, Schmitz M, et al. Increasing incidence of nonfunctional neuroendocrine tumors of the pancreas. American Society of Clinical Oncology Gastrointestinal Cancers Symposium. Orlando, FL., 2007.
4.
Zurück zum Zitat Capella C, Heitz PU, Hofler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425(6):547–560.PubMedCrossRef Capella C, Heitz PU, Hofler H, et al. Revised classification of neuroendocrine tumours of the lung, pancreas and gut. Virchows Arch 1995;425(6):547–560.PubMedCrossRef
5.
Zurück zum Zitat Fernandez-del Castillo C, Rattner DW, Warshaw AL. Standards for pancreatic resection in the 1990s. Arch Surg 1995;130(3):295–299 (discussion 299–300).PubMed Fernandez-del Castillo C, Rattner DW, Warshaw AL. Standards for pancreatic resection in the 1990s. Arch Surg 1995;130(3):295–299 (discussion 299–300).PubMed
6.
Zurück zum Zitat Richter A, Niedergethmann M, Sturm JW, et al. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003;27(3):324–329.PubMedCrossRef Richter A, Niedergethmann M, Sturm JW, et al. Long-term results of partial pancreaticoduodenectomy for ductal adenocarcinoma of the pancreatic head: 25-year experience. World J Surg 2003;27(3):324–329.PubMedCrossRef
7.
Zurück zum Zitat Schmidt CM, Powell ES, Yiannoutsos CT, et al. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg 2004;139(7):718–725 (discussion 725–727).PubMedCrossRef Schmidt CM, Powell ES, Yiannoutsos CT, et al. Pancreaticoduodenectomy: a 20-year experience in 516 patients. Arch Surg 2004;139(7):718–725 (discussion 725–727).PubMedCrossRef
8.
Zurück zum Zitat Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4(6):567–579.PubMedCrossRef Sohn TA, Yeo CJ, Cameron JL, et al. Resected adenocarcinoma of the pancreas—616 patients: results, outcomes, and prognostic indicators. J Gastrointest Surg 2000;4(6):567–579.PubMedCrossRef
9.
Zurück zum Zitat Whipple AO. An evaluation of radical surgery for carcinoma of the pancreas and ampullary region. Ann Intern Med 1949;31(4):624–627.PubMed Whipple AO. An evaluation of radical surgery for carcinoma of the pancreas and ampullary region. Ann Intern Med 1949;31(4):624–627.PubMed
10.
Zurück zum Zitat Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244(1):10–15.PubMedCrossRef Cameron JL, Riall TS, Coleman J, Belcher KA. One thousand consecutive pancreaticoduodenectomies. Ann Surg 2006;244(1):10–15.PubMedCrossRef
11.
Zurück zum Zitat Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995;222(5):638–645.PubMedCrossRef Lieberman MD, Kilburn H, Lindsey M, Brennan MF. Relation of perioperative deaths to hospital volume among patients undergoing pancreatic resection for malignancy. Ann Surg 1995;222(5):638–645.PubMedCrossRef
12.
Zurück zum Zitat Jarufe NP, Coldham C, Orug T, et al. Neuroendocrine tumours of the pancreas: predictors of survival after surgical treatment. Dig Surg 2005;22(3):157–162.PubMedCrossRef Jarufe NP, Coldham C, Orug T, et al. Neuroendocrine tumours of the pancreas: predictors of survival after surgical treatment. Dig Surg 2005;22(3):157–162.PubMedCrossRef
13.
Zurück zum Zitat Norton JA. Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg 2006;10(3):327–331.PubMedCrossRef Norton JA. Surgery for primary pancreatic neuroendocrine tumors. J Gastrointest Surg 2006;10(3):327–331.PubMedCrossRef
14.
Zurück zum Zitat Winchester DP, Stewart AK, Bura C, Jones RS. The National Cancer Data Base: a clinical surveillance and quality improvement tool. J Surg Oncol 2004;85(1):1–3.PubMedCrossRef Winchester DP, Stewart AK, Bura C, Jones RS. The National Cancer Data Base: a clinical surveillance and quality improvement tool. J Surg Oncol 2004;85(1):1–3.PubMedCrossRef
15.
Zurück zum Zitat Guo KJ, Liao HH, Tian YL, et al. Surgical treatment of nonfunctioning islet cell tumor: report of 41 cases. Hepatobiliary Pancreat Dis Int 2004;3(3):469–472.PubMed Guo KJ, Liao HH, Tian YL, et al. Surgical treatment of nonfunctioning islet cell tumor: report of 41 cases. Hepatobiliary Pancreat Dis Int 2004;3(3):469–472.PubMed
16.
Zurück zum Zitat Commission on Cancer. Standards of the Commission on Cancer Volume II: Registry operations and data standards. Chicago: American College of Surgeons, 1998. Commission on Cancer. Standards of the Commission on Cancer Volume II: Registry operations and data standards. Chicago: American College of Surgeons, 1998.
17.
Zurück zum Zitat Facility Oncology Registry Data Standards. Chicago: American College of Surgeons, Commission on Cancer, 2004. Facility Oncology Registry Data Standards. Chicago: American College of Surgeons, Commission on Cancer, 2004.
19.
Zurück zum Zitat Hosmer J, Lemeshow S. Applied Logistic Regression. New York: Wiley, 1999. Hosmer J, Lemeshow S. Applied Logistic Regression. New York: Wiley, 1999.
21.
Zurück zum Zitat Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20(11):2633–2642.PubMedCrossRef Hochwald SN, Zee S, Conlon KC, et al. Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups. J Clin Oncol 2002;20(11):2633–2642.PubMedCrossRef
22.
Zurück zum Zitat Madeira I, Terris B, Voss M, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 1998;43(3):422–427.PubMedCrossRef Madeira I, Terris B, Voss M, et al. Prognostic factors in patients with endocrine tumours of the duodenopancreatic area. Gut 1998;43(3):422–427.PubMedCrossRef
23.
Zurück zum Zitat Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12(4):1083–1092.PubMedCrossRef Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005;12(4):1083–1092.PubMedCrossRef
24.
Zurück zum Zitat Schurr PG, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg 2007;245(2):273–281.PubMedCrossRef Schurr PG, Strate T, Rese K, et al. Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience. Ann Surg 2007;245(2):273–281.PubMedCrossRef
26.
Zurück zum Zitat Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005;241(5):776–783 (discussion 783–785).PubMedCrossRef Touzios JG, Kiely JM, Pitt SC, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg 2005;241(5):776–783 (discussion 783–785).PubMedCrossRef
27.
Zurück zum Zitat Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190(4):432–445.PubMedCrossRef Chamberlain RS, Canes D, Brown KT, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg 2000;190(4):432–445.PubMedCrossRef
28.
Zurück zum Zitat Bilimoria K, Bentrem D, Ko C, et al. National failure to operate on early-stage pancreatic cancer. Ann Surg 2007 (On line). Bilimoria K, Bentrem D, Ko C, et al. National failure to operate on early-stage pancreatic cancer. Ann Surg 2007 (On line).
29.
Zurück zum Zitat O’Connell JB, Maggard MA, Ko CY. Cancer-directed surgery for localized disease: decreased use in the elderly. Ann Surg Oncol 2004;11(11):962–969.PubMedCrossRef O’Connell JB, Maggard MA, Ko CY. Cancer-directed surgery for localized disease: decreased use in the elderly. Ann Surg Oncol 2004;11(11):962–969.PubMedCrossRef
30.
Zurück zum Zitat Makary MA, Winter JM, Cameron JL, et al. Pancreaticoduodenectomy in the very elderly. J Gastrointest Surg 2006;10(3):347–356.PubMedCrossRef Makary MA, Winter JM, Cameron JL, et al. Pancreaticoduodenectomy in the very elderly. J Gastrointest Surg 2006;10(3):347–356.PubMedCrossRef
31.
Zurück zum Zitat Bilimoria K, Bentrem D, Ko C, et al. National failure to operate on early-stage pancreatic cancer in the United States. 2007 (in press). Bilimoria K, Bentrem D, Ko C, et al. National failure to operate on early-stage pancreatic cancer in the United States. 2007 (in press).
32.
Zurück zum Zitat Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998;280(20):1747–1751.PubMedCrossRef Begg CB, Cramer LD, Hoskins WJ, Brennan MF. Impact of hospital volume on operative mortality for major cancer surgery. JAMA 1998;280(20):1747–1751.PubMedCrossRef
33.
Zurück zum Zitat Cameron JL, Pitt HA, Yeo CJ, et al. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 1993;217(5):430–435 (discussion 435–438).PubMedCrossRef Cameron JL, Pitt HA, Yeo CJ, et al. One hundred and forty-five consecutive pancreaticoduodenectomies without mortality. Ann Surg 1993;217(5):430–435 (discussion 435–438).PubMedCrossRef
34.
Zurück zum Zitat Chung JC, Choi DW, Jo SH, et al. Malignant nonfunctioning endocrine tumors of the pancreas: Predictive factors for survival after surgical Treatment. World J Surg 2007. Chung JC, Choi DW, Jo SH, et al. Malignant nonfunctioning endocrine tumors of the pancreas: Predictive factors for survival after surgical Treatment. World J Surg 2007.
35.
Zurück zum Zitat Liang H, Wang P, Wang XN, et al. Management of nonfunctioning islet cell tumors. World J Gastroenterol 2004;10(12):1806–1809.PubMed Liang H, Wang P, Wang XN, et al. Management of nonfunctioning islet cell tumors. World J Gastroenterol 2004;10(12):1806–1809.PubMed
36.
Zurück zum Zitat Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001;130(6):1078–1085.PubMedCrossRef Solorzano CC, Lee JE, Pisters PW, et al. Nonfunctioning islet cell carcinoma of the pancreas: survival results in a contemporary series of 163 patients. Surgery 2001;130(6):1078–1085.PubMedCrossRef
37.
Zurück zum Zitat Tomassetti P, Campana D, Piscitelli L, et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 2005;16(11):1806–1810.PubMedCrossRef Tomassetti P, Campana D, Piscitelli L, et al. Endocrine pancreatic tumors: factors correlated with survival. Ann Oncol 2005;16(11):1806–1810.PubMedCrossRef
38.
Zurück zum Zitat Venkatesh S, Ordonez NG, Ajani J, et al. Islet cell carcinoma of the pancreas. A study of 98 patients. Cancer 1990;65(2):354–357.PubMedCrossRef Venkatesh S, Ordonez NG, Ajani J, et al. Islet cell carcinoma of the pancreas. A study of 98 patients. Cancer 1990;65(2):354–357.PubMedCrossRef
Metadaten
Titel
Clinicopathologic Features and Treatment Trends of Pancreatic Neuroendocrine Tumors: Analysis of 9,821 Patients
verfasst von
Karl Y. Bilimoria
James S. Tomlinson
Ryan P. Merkow
Andrew K. Stewart
Clifford Y. Ko
Mark S. Talamonti
David J. Bentrem
Publikationsdatum
01.11.2007
Verlag
Springer-Verlag
Erschienen in
Journal of Gastrointestinal Surgery / Ausgabe 11/2007
Print ISSN: 1091-255X
Elektronische ISSN: 1873-4626
DOI
https://doi.org/10.1007/s11605-007-0263-3

Weitere Artikel der Ausgabe 11/2007

Journal of Gastrointestinal Surgery 11/2007 Zur Ausgabe

Update Chirurgie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

S3-Leitlinie „Diagnostik und Therapie des Karpaltunnelsyndroms“

Karpaltunnelsyndrom BDC Leitlinien Webinare
CME: 2 Punkte

Das Karpaltunnelsyndrom ist die häufigste Kompressionsneuropathie peripherer Nerven. Obwohl die Anamnese mit dem nächtlichen Einschlafen der Hand (Brachialgia parästhetica nocturna) sehr typisch ist, ist eine klinisch-neurologische Untersuchung und Elektroneurografie in manchen Fällen auch eine Neurosonografie erforderlich. Im Anfangsstadium sind konservative Maßnahmen (Handgelenksschiene, Ergotherapie) empfehlenswert. Bei nicht Ansprechen der konservativen Therapie oder Auftreten von neurologischen Ausfällen ist eine Dekompression des N. medianus am Karpaltunnel indiziert.

Prof. Dr. med. Gregor Antoniadis
Berufsverband der Deutschen Chirurgie e.V.

S2e-Leitlinie „Distale Radiusfraktur“

Radiusfraktur BDC Leitlinien Webinare
CME: 2 Punkte

Das Webinar beschäftigt sich mit Fragen und Antworten zu Diagnostik und Klassifikation sowie Möglichkeiten des Ausschlusses von Zusatzverletzungen. Die Referenten erläutern, welche Frakturen konservativ behandelt werden können und wie. Das Webinar beantwortet die Frage nach aktuellen operativen Therapiekonzepten: Welcher Zugang, welches Osteosynthesematerial? Auf was muss bei der Nachbehandlung der distalen Radiusfraktur geachtet werden?

PD Dr. med. Oliver Pieske
Dr. med. Benjamin Meyknecht
Berufsverband der Deutschen Chirurgie e.V.

S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“

Appendizitis BDC Leitlinien Webinare
CME: 2 Punkte

Inhalte des Webinars zur S1-Leitlinie „Empfehlungen zur Therapie der akuten Appendizitis bei Erwachsenen“ sind die Darstellung des Projektes und des Erstellungswegs zur S1-Leitlinie, die Erläuterung der klinischen Relevanz der Klassifikation EAES 2015, die wissenschaftliche Begründung der wichtigsten Empfehlungen und die Darstellung stadiengerechter Therapieoptionen.

Dr. med. Mihailo Andric
Berufsverband der Deutschen Chirurgie e.V.